1 which evaluated the quality and productivity of the cooperative group effort. It wasn't a very good review. In fact, the committee called for a complete revamping of the cooperative group effort. Importantly, the report affirmed the importance of our cooperative groups and the need to improve the system. Unfortunately, though, reforming a system that was historically based on a culture of independence and competitiveness is not easy. The NCI responded to the IOM report by creating a new entity, the NCTN, 2 which collapsed the 10 existing cooperative groups into 4 adult groups and 1 pediatric group and changed the funding model. As part of this new system, 30 academic institutions, called Lead Academic Participating Sites, will receive additional funding to support infrastructure needs. However, institutions that didn't compete or competed and lost are apparently out of luck, as these grants aren't expected to be offered again for some time. Rumor has it that the NCI is looking for additional costcutting measures (who isn't?) and is addressing this through consolidating common core resources within the network, such as biostatistics support.
I'm not suggesting that any of these moves were or are unwise. I'm just noting that all of these changes have had a significant impact on productivity. The timeline from idea to implementation has slowed considerably. Accrual to open studies is often below target. Investigators with fresh ideas are frustrated. And industry, for the most part, would rather conduct its own studies.
Fundamentally, well-designed and flawlessly conducted clinical trials that ask important questions are at the core of evidence-based medicine. In fact, I would argue that clinical trials are largely responsible for the dramatic decline seen in death rates from some of the most common cancers. And the US Clinical Trials Cooperative Group Program has played an enormous role in conducting landmark studies, such as those that defined adjuvant therapy in breast and colorectal cancers, two of the biggest success stories.
So my answer to the title question is "yes," we need a publicly funded clinical trials network. The pharmaceutical industry should and will continue to conduct trials with patented drugs for initial and subsequent expanded indications. We need that too. But we also need a forum in which to test ideas when there is no sponsor. We belong to a robust scientific community with many important ideas (involving drugs, devices, assessment of biological behavior, and so forth) that are worthy of our attention. We need to monitor the changes in the system and make sure that our public clinical trials network is efficient and productive. Future generations will be better for it.
